Adalimumab for the treatment of psoriasis

Expert Review of Dermatology

Volumn 4, Issue 1, 2009, Pages 15-21

  Warren, Richard B ^a   Griffiths, Christopher E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Adalimumab; Biologic; Psoriasis

Indexed keywords

ABT 874; ADALIMUMAB; ALEFACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; INFLUENZA VACCINE; LIVE VACCINE; METHOTREXATE; PLACEBO; PNEUMOCOCCUS VACCINE; STELARA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB;

ABSCESS; ARTICLE; CELLULITIS; CLINICAL TRIAL; DEMYELINATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; HUMAN; LUPUS LIKE SYNDROME; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; SOFT TISSUE INFECTION; SPONTANEOUS ABORTION; TREATMENT CONTRAINDICATION; TUBERCULOSIS;

EID: 69949156464     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.4.1.15     Document Type: Article

References (35)

1. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 370, 263-271 (2007).
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 41, 401-407 (1999).
3. Warren RB, Griffiths CE. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin. Dermatol. 26, 438-447 (2008).
4. Kimball AB, Gordon KB, Langley RG et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, Phase 2 trial. Arch. Dermatol. 144, 200-207 (2008).
5. Calabrese LH. Molecular differences in anticytokine therapies. Clin. Exp. Rheumatol. 21, 241-248 (2003).
6. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin. Arthritis Rheum. 34, 12-18 (2005).
7. Electronic Medicines Compendium. Electronic Medicines Compendium Humira (adalimumab). Summary of product characteristics: adalimumab (2008).
8. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol. 55, 598-606 (2006).
9. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid, Dermatologica 157, 238-244 (1978).
10. Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled Phase III trial. J. Am. Acad. Dermatol. 58, 106-115 (2008).
11. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br. J. Dermatol. 158, 558-566 (2008).
12. Gordon K, Tyring S, Gu Y, Okun M. Efficacy and safety results in patients with psoriasis treated continuously with adalimumab for 100 weeks. Presented at: Fall Clinical Dermatology Conference. Las Vegas, NV, USA, 16-19 October 2008.
13. Revicki DV, Willian MK, Menter A et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J. Dermatolog. Treat. 18, 341-350 (2007).
14. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210-216 (1994).
15. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52, 3279-3289 (2005).
16. Mease PJ, Ory P, Sharp JT et al. Adalimumab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann. Rheum. Dis. (Epub ahead of print) (2008).
17. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727-735 (1995).
18. Hyrich KL, Symmons DP, Watson KD, Silman AJ. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum. 54, 2701-2702 (2006).
19. Winger EE, Reed JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am. J. Reprod. Immunol. 60, 8-16 (2008).
20. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 60, 800-805 (2005).
21. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 59, 996-1001 (2008).
22. Harrison MJ, Dixon WG, Watson KD et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-TNFα therapy. Results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. (2008) (Epub ahead of print).
23. Gelinck LB, van der Bijl AE, Beyer WE et al. The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination. Ann. Rheum. Dis. 67, 713-716 (2008).
24. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J. Rheumatol. 34, 272-279 (2007).
25. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014-2022 (2003).
26. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a Phase III, multicentre, double-blind trial. Lancet 366, 1367-1374 (2005).
27. Gordon KB, Papp K, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290, 3073-3080 (2003).
28. Gottlieb A, Korman NJ, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J. Am. Acad. Dermatol. 58, 851-864 (2008).
29. Leonardi C, Menter A, Hamilton T et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br. J. Dermatol. 158, 1107-1116 (2008).
30. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 296, 1735-1741 (2006).
31. Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch. Dermatol. 143, 1493-1499 (2007).
32. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch. Dermatol. Res. 298, 309-319 (2006).
33. + T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis. J. Immunol. 181, 4733-4741 (2008).
34. Ortonne JP. Clinical response to alefacept: results of a Phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 17(Suppl. 2), 12-16 (2003).
35. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675-1684 (2008).